CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Financial Flexibility Index
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Financial Flexibility Index of -1.20x as of December 2025. Free cash flow of $-1.36 Million (operating CF $-1.59 Million minus capex $231.75K) represents -1% of total liabilities ($1.13 Million). Also explore how fast is CytoMed Therapeutics Limited Ordinary Sh growing its equity to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
CytoMed Therapeutics Limited Ordinary Shares Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for CytoMed Therapeutics Limited Ordinary Shares across 7 annual periods. Check how strategically is CytoMed Therapeutics Limited Ordinary Sh's equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Year-by-year free cash flow to debt coverage for CytoMed Therapeutics Limited Ordinary Shares. For the full company profile including market capitalisation, see how much is CytoMed Therapeutics Limited Ordinary Sh worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.65x | $-2.99 Million | $-3.70 Million | $1.13 Million | ▼ -196.5% |
| 2024 | -0.89x | $-669.32K | $-1.69 Million | $749.76K | ▲ +70.1% |
| 2023 | -2.99x | $-2.55 Million | $-2.59 Million | $852.28K | ▼ -1278.2% |
| 2022 | -0.22x | $-751.12K | $-1.10 Million | $3.46 Million | ▲ +33.1% |
| 2021 | -0.32x | $-838.33K | $-1.27 Million | $2.59 Million | ▼ -61.5% |
| 2020 | -0.20x | $-507.02K | $-692.31K | $2.53 Million | ▼ -137.1% |
| 2019 | 0.54x | $401.13K | $-471.85K | $742.31K | — |